EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Essex Bio-Technology Reports 1st H 2024 Net Profit of HK$157.4 Million Poised for Future Success Underpinned by Proven Product Base and Promising Pipeline of Products

2024.08.26

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2024

2024.08.26

Date

Title

2021-03-12

Essex Bio-Technology Announces 2020 Financial Results Sales of HK$654m & PAT of HK$170m recorded in 2nd Half

2021-02-24

Essex Bio-Technology and Mitotech announce positive outcome of VISTA-2 Phase 3 clinical study in Dry Eye Disease

2021-01-29

Essex-Biotechnology Announces Bevacizumab for wAMD Has Received Clinical Trial Approval in Australia

2020-11-23

Essex Bio-Technology Included in Forbes Asia's Best Under A Billion 2020

2020-10-15

Essex and Henlius Entered into a Global Co-Development and Exclusive License Agreement to Jointly Develop Bevacizumab for Treatment of Ophthalmic Diseases

2020-08-25

Essex Bio-Technology and Mitotech Complete Enrollment in VISTA-2 – a Pivotal Phase 3 Clinical Study of SkQ1 for Dry Eye Disease

2020-08-18

Essex Bio-Technology Reports First Half 2020 Financial Results

2020-08-10

Essex Bio-Technology Enters into Global Out-licence Agreement with Kelun-Biotech

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT